OnKure CFO receives option grant and repricing
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received a new option grant for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring in 2036.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
OnKure Therapeutics, Inc. reported that Chief Financial Officer Jason A. Leverone received a new option grant for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring in 2036. He also participated in a one-time option repricing, with previously granted options for 5,781, 5,322, and 130,611 shares surrendered to the issuer and concurrently regranted with a reduced exercise price of $4.14 per share, while maintaining the same vesting schedules, expiration dates, and number of underlying shares. Footnotes state that repriced options require paying the original higher exercise price if exercised before the end of a defined Retention Period.
Insider Trade Summary
7 transactions reported
Mixed
7 txns
Insider
Leverone Jason A.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) F1 | 50,000 | $0.00 | $0.00 |
| Disposition | Employee Stock Option (right to buy F3, F4, F2 | 5,781 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy F3, F4, F2 | 5,781 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F5 | 5,322 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F5 | 5,322 | -- | -- |
| Disposition | Employee Stock Option (right to buy) F3, F4, F6 | 130,611 | -- | -- |
| Grant/Award | Employee Stock Option (right to buy) F3, F4, F6 | 130,611 | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 185,933 contracts (Direct);
Employee Stock Option (right to buy — 5,781 contracts (Direct)
Footnotes (6)
- F1. 1/48th of the shares subject to the option shall vest on September 7, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F2. All of the shares subject to this option are fully vested and exercisable as of the date hereof.
- F3. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
- F4. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.
- F5. 1/48th of the shares subject to the option vested on May 1, 2023 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
- F6. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Key Figures
New option grant: 50,000 shares at $4.14
Repriced options 1: 5,781 shares from $21.20 to $4.14
Repriced options 2: 5,322 shares from $13.99 to $4.14
+1 more
4 metrics
New option grant
50,000 shares at $4.14
Employee stock option granted to CFO on August 7, 2026, expiring August 6, 2036
Repriced options 1
5,781 shares from $21.20 to $4.14
Options expiring January 10, 2032 repriced under Option Repricing
Repriced options 2
5,322 shares from $13.99 to $4.14
Options expiring August 29, 2033 repriced under Option Repricing
Repriced options 3
130,611 shares from $18.20 to $4.14
Options expiring October 3, 2034 repriced under Option Repricing
Key Terms
Option Repricing, Retention Period, premium exercise price, Change in Control
4 terms
Option Repricing financial
"The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing")"
Retention Period financial
"before the end of a "Retention Period" through which the option holder must remain in service"
Change in Control financial
"ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity award did OnKure Therapeutics (OKUR) grant to its CFO?
OnKure granted CFO Jason A. Leverone an option for 50,000 shares of Class A common stock at an exercise price of $4.14 per share, expiring on August 6, 2036, with monthly vesting beginning September 7, 2026, contingent on continued service.
What is the stock option repricing disclosed by OnKure Therapeutics (OKUR)?
OnKure implemented a one-time Option Repricing effective August 7, 2026, lowering exercise prices to $4.14 for options at or above $10.00 per share held by continuing employees and certain service providers, including the CFO, without changing vesting schedules, expiration dates, or share amounts.
Which of the OnKure (OKUR) CFO’s options were repriced and to what level?
Options covering 5,781 shares at $21.20, 5,322 shares at $13.99, and 130,611 shares at $18.20 were returned to the issuer and concurrently regranted with a reduced exercise price of $4.14 per share, maintaining existing vesting and expiration terms.
How does the Retention Period affect repriced options at OnKure Therapeutics (OKUR)?
If a holder exercises a repriced option before the end of the Retention Period, they must pay a premium exercise price equal to the original higher exercise price. The Retention Period runs from August 7, 2026 until February 7, 2028 or an earlier qualifying Change in Control.
Are all of the repriced OnKure (OKUR) options for the CFO vested?
Footnotes state that certain options, such as those vesting monthly since May 1, 2023 and November 4, 2024, are fully vested and exercisable as of the reported date, while the new 50,000-share grant will vest monthly starting September 7, 2026, subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
